Trial Profile
A Phase 1, Open Label Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Nov 2013
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary) ; Lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors Vertex Pharmaceuticals
- 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 23 Oct 2013 New trial record